

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.
See The American Inventors Protection Act of 1999 (AIPA).


<i>Application Number</i>	09/975,219
<i>Filing Date</i>	10/11/2001
<i>First Named Inventor</i>	Ferdinand S. Signey
<i>Group Art Unit</i>	3724
<i>Examiner Name</i>	Windmuller, John
<i>Attorney Docket Number</i>	TI-27954

This is a Request for Continued Examination (REC) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Annuity Examination and Annuinal Adjustment Deadline Interim Rule at End Date 10/29/2000 (MAY 29, 2000) 2220 OF 2220 (MAY 29, 2000) which

1	Submission required under 37 C.F.R. §
<p>a <input checked="" type="checkbox"/> Previously submitted</p> <ul style="list-style-type: none"> i. <input checked="" type="checkbox"/> Consider the amendments(s)/reply under 37 C.F.R. § 1.116 previously filed on <u>March 2, 2004</u>. (Any unentered amendment(s) referred to above will be entered). ii. <input type="checkbox"/> Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____. iii. <input type="checkbox"/> Other _____ <p>b <input type="checkbox"/> Enclosed</p> <ul style="list-style-type: none"> i. <input type="checkbox"/> Amendment/Reply ii. <input type="checkbox"/> Affidavit(s)/Declaration(s) iii. <input type="checkbox"/> Information Disclosure Statement (IDS) iv. <input type="checkbox"/> Other _____ 	
2	Miscellaneous
<p>a <input type="checkbox"/> Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17 (l) required)</p> <p>b <input type="checkbox"/> Other _____</p>	
3	Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.
<p>a <input checked="" type="checkbox"/> The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. <u>20-0668</u>, Texas Instruments Incorporated.</p> <ul style="list-style-type: none"> i. <input checked="" type="checkbox"/> RCE fee required under 37 C.F.R. § 1.17(e) ii. <input checked="" type="checkbox"/> Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) iii. <input type="checkbox"/> Other _____ <p>b <input type="checkbox"/> Check in the amount of \$_____ enclosed</p> <p>c <input type="checkbox"/> Payment by credit card (Form PTO-2038 enclosed)</p>	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type)	W. Daniel Swayze Jr.	Registration No. (Attorney / Agent)	34,478
Signature			

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print or Type)	Tommie Chambers	
Signature	Tommie Chambers	Date 3-22-04

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND FEES AND COMPLETED FORMS TO THE FOLLOWING ADDRESS: Commissioner for Patents, Box RCE, Washington, DC 20231.